IgM Rheumatoid Factor Research Articles

FRI0062 A prediction rule for the development of arthritis in seropositive arthralgia patients

BackgroundPatients presenting with arthralgia and a positive test for anti-cyclic citrullinated peptide antibodies (aCCP) and/or IgM rheumatoid factor (IgM-RF) (seropositive) are at risk for developing RA.ObjectivesTo predict the development of...

THU0050 Circulating Lung Surfactant Protein D (SP-D) Differs Between Rheumatoid Arthritis (RA) Patients According to Anti-Citrullinated Protein Antibody (Anti-CCP) and IGM-Rheumafactor (IGM-RF) Status

BackgroundSubclinical lung inflammation has been proposed as a triggering mechanism for the generation of anti-CCP. This concept has recently been supported by imaging studies showing clinically silent parenchymal lung changes...

AB0096 Presence of systemic arthritis autoantibodies in non-ra patients with severe periodontitis

BackgroundAnti-citrullinated protein antibodies (ACPA), rheumatoid factor (RF) and anti-carbamylated proteins (anti-CarP) can be present before clinical manifestation of rheumatoid arthritis (RA). Periodontitis is regarded as a possible risk factor for...

AB0157 The diagnostic performance of a candidate multi-biomarker score in early rheumatoid arthritis

BackgroundIn the early phase of rheumatoid arthritis (RA) the patients do not yet fulfill the criteria for disease1. To meet the need for improved diagnostic tests and algorithms, various serum...

AB0312 Effect of tocilizumab on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis

BackgroundRheumatoid arthritis (RA) is a systemic autoimmune disease characterized by synovial inflammation that eventually results in joint destruction and functional damages. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP)...

THU0003 Correlation of MIR-124 to Extracellular Matrix Protein MMP-3 in Patients with Rheumatoid Arthritis

BackgroundMicroRNAs (miRNAs) are a 21 to 25 nucleotide long, small non-coding RNAs that post-transcriptionally regulate the expression of target genes, and thus modulate biological processes including cell differentiation, proliferation, apoptosis...

SAT0124 Decreased Titer of ANTI-CCP Antibodies and Rheumatoid Factor and Reduction of Post-Switch Memory B Cells After Abatacept Treatment for Rheumatoid Arthritis

BackgroundB cells play a central role in the pathophysiology of Rheumatoid Arthritis (RA). In particular, they can produce rheumatoid factor (RF) and other autoantibodies, including anti-cyclic citrullinated peptide (anti-CCP), whose...

SP0022 Prevention is Better than Cure: A New Dawn for the Management of RA?

Rheumatoid Arthritis (RA) is a prototype immune-mediated inflammatory disease, in which persistent inflammation leads to joint damage, with as a consequence disability, loss of quality of life, reduced ability to...

THU0145 Novel Peptide Biomarkers Detected by Mass Spectrometry Predict Arthritis in Seropositive Arthralgia Patients

BackgroundPersons with IgM-rheumatoid factor and/or anti-CCP in their blood (seropositive) are at increased risk for developing rheumatoid arthritis (RA). In our ongoing seropositive arthralgia cohort, this risk is 40% after...

AB0111 Development of anti–citrullinated protein antibody and rheumatoid factor isotypes in relation to smoking prior to the onset of rheumatoid arthritis

BackgroundWe and others have previously shown that IgG anti–citrullinated protein antibody (ACPA) and rheumatoid factor (RF) precede the development of RA.1, 2 Furthermore, it was shown that other isotypes of...

AB1307 Intra- and interreader reliability of the omeract joint space narrowing score on magnetic resonance imaging and computed tomography in rheumatoid arthritis wrist and metacarpophalangeal joints

BackgroundThe OMERACT RA MRI scoring system (RAMRIS) evaluates bone erosions, bone edema, and synovitis. The system is validated and increasingly used as an outcome measure in RA clinical trials. However,...

AB0304 Predictors of gain in quality adjusted life years in RA patients treated with biologics for one year

BackgroundThe Quality Adjusted Life Year (QALY), based on health-related quality of life measures such as euroqol 5 dimensions (EQ-5D), is an important outcome in rheumatoid arthritis (RA) studies, as it...

AB0304 Clinical and serological response to tocilizumab in patients with rheumatoid arthritis

BackgroundThe role of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) in the response to treatment for rheumatoid arthritis (RA) is not fully understood. Studies investigating changes in the...

AB0259 Characteristics and cardiovascular comorbidities in patients with rheumatoid arthritis in a local patient cohort in russia

BackgroundPatients with Rheumatoid Arthritis (RA) have an increased risk for cardiovascular disease (CVD).ObjectivesTo evaluate CVD prevalence and RA-related factors in RA patients participating in the prospective longitudinal (7 years duration)...

AB0425 Plasma vitamin D levels in relation to insulin resistance and risk of metabolic syndrome in rheumatoid arthritis patients

BackgroundIt has been suggest a link between circulating levels of 25 hydroxyvitamin D [25(OH)D] and metabolic risk factors. It is know that metabolic syndrome (MetS) is strongly predictive of cardiovascular...

AB0707 Arthritis prevalence and biological markers in primary sjÖgren’s syndrome

BackgroundPrimary Sjögren (pSS) is a chronic inflammatory autoimmune disease characterised by lymphocytic infiltration of the exocrine glands. Most patients present Keratoconjuntivitis sicca and xerostomia, and about 40% of them develop...

THU0113 Predictive factors of response to rituximab therapy modify the accelerated atherosclerosis in patients with rheumatoid arthritis

BackgroundIncreased cardiovascular mortality has been associated with rheumatoid arthritis (RA). There are reports indicating that tumor necrosis factor blockers may exert favourable but transient effects on lipid profile, flow mediated...

AB0574 Evaluation of the efficacy of tocilizumab toward the patients with active rheumatoid arthritis of nagasaki prefecture, japan

BackgroundTocilizumab (TCZ) is a humanized anti-interleukin 6 receptor (IL-6R) monoclonal antibody and it was approved in Japan as an antirheumatic drugs in 2008. Evidence of the efficacy of TCZ in...

THU0083 NF-KB-Inducing Kinase (NIK) Expression in Synovial Blood Vessels Correlates with Systemic Markers of Inflammation and Local Disease Activity in Early Arthritis Patients, but is not Disease Specific

BackgroundThe NF-κB family of transcription factors is strongly involved in synovial inflammation. We have previously shown that NF-κB-inducing kinase (NIK) is a key regulator of inflammation-induced angiogenesis in rheumatoid arthritis...

Influence of Adult Height on Rheumatoid Arthritis: Association with Disease Activity, Impairment of Joint Function and Overall Disability

ObjectivesTo investigate whether normal variation of adult height is associated with clinical characteristics in rheumatoid arthritis (RA), including disease activity (DAS28), impairment of joint function (mechanical joint score, MJS) and overall disability (health assessment questionnaire, HAQ).MethodsA cohort (134 males, 287 females) of consecutively recruited RA patients of Northern European origin was studied. Height, weight and demographic information were obtained. A core set of disease measurements, including DAS28, MJS and HAQ, were recorded at baseline, 12 and 24 months. Other clinical variables (e.g. disease duration, IgM rheumatoid factor, antibodies to cyclic citrullinated peptide, C-reactive protein, erythrocyte sedimentation rate) were recorded at baseline. Socioeconomic status, smoking status, comorbid condition, other autoimmune conditions and drug therapy were also recorded. Associations were analyzed using univariate statistics and multivariate linear regression models. Mediation tests were also carried out for evaluating the relationship between gender, height and disease measures.ResultsIn males, height was inversely associated with DAS28, MJS and HAQ (at baseline and over 24 months) independent of other factors (e.g. weight, body mass index, age, disease duration, osteoporosis, autoantibodies, erosive disease, joint replacement, steroid use, smoking status, socioeconomic status and comorbid disease). In females, a similar trend was seen but the relationships were non significant. In the whole population, the association of female gender with more active disease and poor function disappeared after adjustment for height. Mediation analysis indicated that height served as a full mediator in the relationship of gender with disease activity and overall disability. Confirmation of these findings was demonstrated in a second RA population (n = 288).ConclusionAdult height is inversely associated with disease activity, impairment of joint function and overall disability in RA, particularly in males. The association of female sex with more severe disease activity and disability appears to be mediated by smaller stature.